Certified Advisory Corp Takes $209,000 Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Certified Advisory Corp bought a new stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 2,702 shares of the company’s stock, valued at approximately $209,000.

A number of other hedge funds have also made changes to their positions in the business. First Command Advisory Services Inc. increased its stake in GE HealthCare Technologies by 36,900.0% during the 3rd quarter. First Command Advisory Services Inc. now owns 370 shares of the company’s stock worth $25,000 after buying an additional 369 shares during the period. ORG Partners LLC grew its holdings in GE HealthCare Technologies by 174.2% during the 3rd quarter. ORG Partners LLC now owns 425 shares of the company’s stock worth $29,000 after acquiring an additional 270 shares in the last quarter. Fortitude Family Office LLC acquired a new position in GE HealthCare Technologies during the 4th quarter worth $29,000. Turtle Creek Wealth Advisors LLC acquired a new position in GE HealthCare Technologies during the 4th quarter worth $30,000. Finally, Sachetta LLC acquired a new position in GE HealthCare Technologies during the 4th quarter worth $31,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In other GE HealthCare Technologies news, CEO Jan Makela sold 20,227 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $81.57, for a total transaction of $1,649,916.39. Following the sale, the chief executive officer now directly owns 63,348 shares in the company, valued at approximately $5,167,296.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other GE HealthCare Technologies news, insider Frank R. Jimenez bought 1,315 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were acquired at an average cost of $76.52 per share, for a total transaction of $100,623.80. Following the acquisition, the insider now directly owns 75,796 shares of the company’s stock, valued at $5,799,909.92. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jan Makela sold 20,227 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $81.57, for a total transaction of $1,649,916.39. Following the completion of the sale, the chief executive officer now owns 63,348 shares in the company, valued at $5,167,296.36. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

GE HealthCare Technologies Stock Performance

GE HealthCare Technologies stock traded down $0.62 during midday trading on Thursday, reaching $80.00. 187,776 shares of the stock traded hands, compared to its average volume of 3,225,267. The company has a current ratio of 1.06, a quick ratio of 0.83 and a debt-to-equity ratio of 1.11. The firm has a fifty day moving average price of $85.49 and a two-hundred day moving average price of $80.42. The firm has a market cap of $36.52 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 2.95 and a beta of 1.26. GE HealthCare Technologies Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Tuesday, April 30th. The company reported $0.90 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.90. GE HealthCare Technologies had a net margin of 8.05% and a return on equity of 25.32%. The firm had revenue of $4.65 billion during the quarter, compared to analyst estimates of $4.80 billion. During the same period in the previous year, the business posted $0.85 EPS. GE HealthCare Technologies’s revenue was down 1.2% on a year-over-year basis. On average, equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 15th. Shareholders of record on Friday, April 19th were given a dividend of $0.03 per share. The ex-dividend date was Thursday, April 18th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.15%. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.51%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GEHC. Morgan Stanley raised their price objective on shares of GE HealthCare Technologies from $74.00 to $86.00 and gave the stock an “equal weight” rating in a report on Monday, February 12th. Evercore ISI raised their price objective on shares of GE HealthCare Technologies from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. HSBC began coverage on shares of GE HealthCare Technologies in a report on Thursday, February 15th. They issued a “buy” rating and a $100.00 price target for the company. UBS Group raised shares of GE HealthCare Technologies from a “sell” rating to a “neutral” rating and lifted their price target for the company from $66.00 to $88.00 in a report on Monday, February 12th. Finally, Citigroup lifted their price target on shares of GE HealthCare Technologies from $88.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.80.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.